This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial of Poly-L-lactic Acid (Sculptra Aesthetic) for the Treatment of Cellulite of the Buttocks and Thighs

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04830722
Recruitment Status : Unknown
Verified April 2021 by Leslie Laser Aguilar, Goldman, Butterwick, Fitzpatrick and Groff.
Recruitment status was:  Recruiting
First Posted : April 5, 2021
Last Update Posted : April 12, 2021
Sponsor:
Collaborator:
Galderma R&D
Information provided by (Responsible Party):
Leslie Laser Aguilar, Goldman, Butterwick, Fitzpatrick and Groff

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
clinical trial is to assess the safety, efficacy and patient satisfaction associated with the treatment of cellulite of the buttocks and thighs with injectable poly-L-lactic acid (PLLA), or Sculptra® Aesthetic

Condition or disease Intervention/treatment Phase
Cellulite Device: Sculptra Aesthetic Not Applicable

Detailed Description:
Enrolled subjects will be randomized to 2 treatment groups: "Right side treated" and "Left side treated". All subjects will receive three, single-sided injections of Sculptra Aesthetic, performed 1 month apart. Treatments will be provided to one side randomly assigned to either "right side" or "left side". The non-treatment side will receive bacteriostatic water, injected in the same manner as Sculptra Aesthetic. Up to four (4) vials of Sculptra Aesthetic, diluted at 16 mL, will be used per treatment session.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Enrolled subjects will be randomized to 2 treatment groups: "Right side treated" and "Left side treated". All subjects will receive three, single-sided injections of Sculptra Aesthetic, performed 1 month apart. Treatments will be provided to one side randomly assigned to either "right side" or "left side". The non-treatment side will receive bacteriostatic water, injected in the same manner as Sculptra Aesthetic.
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Single Center, Double Blinded, Split-body Clinical Trial of Poly-L-lactic Acid (Sculptra Aesthetic) for the Treatment of Cellulite of the Buttocks and Thighs
Actual Study Start Date : April 9, 2021
Estimated Primary Completion Date : April 1, 2022
Estimated Study Completion Date : June 1, 2022

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Sculptra Aesthetic Side
the treatment area side (an area side is considered either buttock and/or thigh) (left or right-depends on randomization) will receive up to two vials of Sculptra Aesthetic, for a total of 4 vials in one treatment session if 2 areas qualify.
 Device: Sculptra Aesthetic
One treatment side treated with Sculptra will be compared to the other side treated with bacteriostatic water (placebo) -same volume
Placebo Comparator: Placebo side
the treatment area side (an area side is considered either buttock and/or thigh) (left or right-depends on randomization) will receive 16 cc of bacteriostatic water, for up to 64 ccs of bacteriostatic water to match the volume injected on the active side
 Device: Sculptra Aesthetic
One treatment side treated with Sculptra will be compared to the other side treated with bacteriostatic water (placebo) -same volume


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Assessing Safety [ Time Frame: 1 year ]
    Assessing safety of treatment of cellulite of the buttocks and thighs with injectable poly-L-lactic acid (PLLA), or Sculptra® Aesthetic (Galderma Laboratories, Fort Worth, TX) using Evaluation of side effects by subject and investigator

  2. Assessing Efficacy [ Time Frame: 1 year ]
    Assessing efficacy of treatment of cellulite of the buttocks and thighs with injectable poly-L-lactic acid (PLLA), or Sculptra® Aesthetic (Galderma Laboratories, Fort Worth, TX) using Subject and Blinded Investigator GAIS and Blinded Investigator Hexsel Grading Scale, Galderma Cellulite Grading Scale, and end of study iodentification of correct treatment side using side by side photography before unblinding.

  3. Assessing Patient Satisfaction [ Time Frame: 1 year ]
    Assessing patient satisfaction of treatment of cellulite of the buttocks and thighs with injectable poly-L-lactic acid (PLLA), or Sculptra® Aesthetic (Galderma Laboratories, Fort Worth, TX) using a patient satisfaction questionnaire


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Female adults age 30 to 60 who meet inclusion and exclusion criteria.
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adult females age 30 to 60
  • Both buttocks and/or both posterolateral thighs with a score of mild (1-5) to moderate (6-10 according to the Hexsel, Dal'Forno & Hexsel Cellulite Severity Scale (CSS), and a laxity score using the Hexsel, Dal'Forno & Hexsel Cellulite Severity Scale of 1 (slight) or 2 (moderate). Must be the same score on both sides of the same area (ie: if 1 on one buttock, must be 1 on the other buttock but can be a 2 on the thigh, as long as the other thigh is also a 2)
  • Must be willing to give and sign an informed consent form and photographic release form.
  • Must have had a stable body weight for at least 6 months prior to study entry.
  • Must be willing to maintain usual sun exposure, diet, and exercise routines for the duration of the study.
  • Subject agrees to avoid tanning or use of sunless tanner during the entire course of the study.
  • Negative urine pregnancy test results at the time of study entry (if applicable).
  • For female subjects of childbearing potential, must be willing to use an acceptable form of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment participation.
  • A female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation.
  • Acceptable methods of birth control are: oral contraceptives, contraceptive patches/rings/implants, Implanon®, Depo-Provera®, double-barrier methods (e.g. condoms and spermicide), abstinence and/or vasectomies of partner with a documented second acceptable method of birth control, should the subject become sexually activity.
  • Must be willing to comply with study treatments and complete the entire course of the study.
  • Cellulite that improves when the skin of the buttocks or thighs are stretched or distended superiorly.

Exclusion Criteria:

  • Use of any of the following for the treatment of cellulite on either thigh or either buttock within the timelines identified below or intends to use any of the following at any time during the course of the study:
  • Liposuction during the 12-month period prior to study treatment.
  • Injections (eg, mesotherapy, dermal fillers, biostimulatory fillers, clostridium collagenase histolyticum); radiofrequency device treatments; laser treatment; buttock or thigh implant treatment; cryolipolysis; or surgery (including subcision and/or powered subcision) during the 24-month period before injection of study treatment.
  • Any investigational treatment for cellulite on a buttock or thigh during the 12-month period before the injection of study treatment.
  • Endermologie or similar treatments during the 6 month period before injection of study treatment.
  • Massage therapy during the 3-month period before injection of study treatment.
  • Creams (eg, Tretinoin, Celluvera™, TriLastin®) and/or home therapies to prevent or treat cellulite during the two week period before injection of study treatment.
  • Subjects with scarring in treatment areas.
  • Has any of the following local conditions in the areas to be treated (both buttocks or both thighs):
  • History of lower extremity thrombosis or post-thrombosis syndrome.
  • Vascular disorder (eg, varicose veins)
  • A subject with tattoos or permanent implants in the treatment areas.
  • A subject with history of or the presence of any skin condition/disease in the treatment area that might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema, psoriasis).
  • Subject who spray tanned or used sunless tanner in the treatment area 4 weeks prior to study treatment.
  • A subject with an active bacterial, fungal, or viral infection in the treatment area.
  • A subject with a significant history or current evidence of a medical, psychological, or other disorder that, in the investigator's opinion, would preclude enrollment into the study.
  • Any history of bleeding or coagulation disorders.
  • History of lidocaine sensitivity deemed by the investigator to preclude patient from enrolling in the study.
  • A subject planning any other cosmetic procedure to the study treatment area during the study period, other than the treatment that will be performed by the investigator.
  • Presence of incompletely healed wound in treatment area.
  • Non-Ablative laser to the treatment area in the last 3 months.
  • A female subject who is pregnant, nursing an infant or planning a pregnancy during the study.
  • Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04830722


Contacts
Layout table for location contacts
Contact: Sherif Research Director, MD 8586571004 SMikhail@clderm.com
Contact: Leslie Aguilar, BA 18586571004 laguilar@clderm.com

Locations
Layout table for location information
United States, California
Cosmetic Laser Dermatology/West Dermatology Research Center Recruiting
San Diego, California, United States, 92121
Contact: Leslie Aguilar, BA    858-657-1004    LAguilar@CLDerm.com   
Contact: Sherif Mikhail, MD    8586571004    SMikhail@clderm.com   
Principal Investigator: Sabrina Fabi, MD         
Sponsors and Collaborators
Goldman, Butterwick, Fitzpatrick and Groff
Galderma R&D
Investigators
Layout table for investigator information
Principal Investigator: Sabrina Fabi, MD Cosmetic Laser Dermatology
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications:

Layout table for additonal information
Responsible Party: Leslie Laser Aguilar, Regulatory Affairs Administrator, Goldman, Butterwick, Fitzpatrick and Groff
ClinicalTrials.gov Identifier: NCT04830722    
Other Study ID Numbers: Sculptra-Aesthetic-2021
First Posted: April 5, 2021    Key Record Dates
Last Update Posted: April 12, 2021
Last Verified: April 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Cellulite
Skin Manifestations